Diabetes and elderly
-
Upload
gowri-shanker -
Category
Documents
-
view
95 -
download
0
Transcript of Diabetes and elderly
![Page 1: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/1.jpg)
Challenges, Goals and Therapeutics in the Elderly
Dr.S.Venkatraman MD.,
![Page 2: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/2.jpg)
Aging and Society2010 Projection
CountryUnder 15
yrs old65 yrs oldand over
Egypt 34.9 5.2
Ethiopia 60.3 3.6
France 18.0 17.3
Germany 14.3 20.1
India 33.6 6.1
Indonesia 31.9 6.7
Iran 28.5 5.3
Iraq 50.3 3.9
Italy 13.1 20.5
Japan 14.5 21.9
Kenya 38.0 3.7
2010 Projection
CountryUnder 15
yrs old65 yrs oldand over
World 30.0 8.6
Argentina 27.3 12.3
Australia 20.4 15.3
Bangladesh 34.5 4.5
Brazil 26.4 7.5
Cambodia 47.3 4.5
Canada 18.2 15.5
Chile 25.1 10.2
China 22.5 8.9
Colombia 33.1 6.6
Cuba 18.1 12.5Age Distribution by Country: 2010 Projection (in percent)
Source: U.S. Bureau of the Census. 2001. Statistical Abstract of the United States 2001. Washington, DC: U.S. Government Printing Office. Table 1328 on p. 834. Also accessible at http:www.census.gov/prod/2002pubs/01statab/stat-ab01.html.
![Page 3: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/3.jpg)
High level of associated comorbidities Increased risk of cognitive dysfunction and mood disorder causing more complex decisio makingIncreased vulnerability to hypoglycaemiaAltered drug metabolism Unstructured specialist and primary care follow up Increased risk of inpatient mortality
![Page 4: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/4.jpg)
1.What is the epidemiology and pathogenesis of diabetes in older adults?
2.What is the evidence for preventing and treating diabetes and its common comorbidities in older adults?
3.What issues need to be considered in individualizing treatment recommendations for older adults?
4.What current guidelines exist for treating diabetes in older adults?
5.What are consensus recommendations for treating older adults with or at risk for diabetes?
![Page 5: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/5.jpg)
1.What is the epidemiology and pathogenesis of diabetes in older adults?
2.What is the evidence for preventing and treating diabetes and its common comorbidities in older adults?
3.What issues need to be considered in individualizing treatment recommendations for older adults?
4.What current guidelines exist for treating diabetes in older adults?
5.What are consensus recommendations for treating older adults with or at risk for diabetes?
![Page 6: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/6.jpg)
![Page 7: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/7.jpg)
The incidence of diabetes increases with age until about age 65 years, after which both incidence and prevalence seem to level off.older adults with diabetes may either have incident disease (diagnosed after age 65 years) or long-standing diabetes with onset in middle age or earlier.
![Page 8: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/8.jpg)
![Page 9: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/9.jpg)
Aging and insulin secretion Am J Physiol Endocrinol Metab284: E7–E12, 2003;
![Page 10: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/10.jpg)
1.What is the epidemiology and pathogenesis of diabetes in older adults?
2.What is the evidence for preventing and treating diabetes and its common comorbidities in older adults?
3.What issues need to be considered in individualizing treatment recommendations for older adults?
4.What current guidelines exist for treating diabetes in older adults?
5.What are consensus recommendations for treating older adults with or at risk for diabetes?
![Page 11: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/11.jpg)
Diabetes mellitus accelerates aging
Diabetes is associated with a decrease in DNA unwinding rate, increased collagen cross-linking, increased capillary basement membrane thickening, increased oxidative damage.
These basic changes result in increased clinical signs of aging.
![Page 12: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/12.jpg)
![Page 13: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/13.jpg)
Various trials targeting glycaemic control
UKPDSACCORDADVANCE VADT
![Page 14: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/14.jpg)
Most Intensive Less Intensive Least Intensive
Patient Age
Disease Duration
40 45 50 55 60 65 70 75
5 10 15 20
Other Comorbidities
None Few/Mild Multiple/Severe
Hypoglycemia RiskLow HighModerate
8.0%6.0% 7.0%
Established Vascular ComplicationsNone Early Micro Advanced Micro
PsychosocioeconomicConsiderationsHighly Motivated, Adherent,Knowledgeable, Excellent Self-Care Capacities, & Comprehensive Support Systems
Less motivated, Non-adherent, Limited insight,
Poor Self-Care Capacities, & Weak Support Systems
Cardiovascular
Individualizing Glycemic Targets in T2DM
Ismail-Beigi, F., et al. Ann Inter Med. 154:554-559, 201114
![Page 15: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/15.jpg)
JNC 8
Threshold = Goal< 60 Years : 140 / 90Diabetic, CKD : 140/90
![Page 16: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/16.jpg)
ACOMPLISH
![Page 17: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/17.jpg)
ACCORD
Non Fatal Stroke (P=0.03)
119 mmHg
133 mmHg
![Page 18: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/18.jpg)
ELDERS
![Page 19: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/19.jpg)
JNC 8
Threshold = Goal > 60 Years : 150 / 90
![Page 20: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/20.jpg)
Elder SBP
Trial Age Base SBP Achieved
SHEP 1991 >60 170 143Syst Eur 1997 >60 174 161HyVET 2008 >80 173 143
![Page 21: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/21.jpg)
![Page 22: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/22.jpg)
Lipids
There are no large trials of lipid-lowering interventions specifically in older adults with diabetes.Cardiovascular prevention with statins, especially secondary benefit, emerges fairly quickly (within 1–2 years) - statins may be indicated in nearly all older adults with diabetes except those with very limited life expectancy.
![Page 23: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/23.jpg)
![Page 24: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/24.jpg)
In populations without diabetes, the greatest absolute benefit of aspirin therapy (75–162 mg) is for individuals with a 10-year risk of coronary heart disease of 10% or greater .diabetes and aged have increased cardiovascular events and aspirin for secondary prevention should be considered in all.
the benefits of aspirin for primary prevention of CVD events have not been thoroughly elucidated in older adults with diabetes and must be balanced against risk of adverse events such as bleeding.
![Page 25: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/25.jpg)
1.What is the epidemiology and pathogenesis of diabetes in older adults?
2.What is the evidence for preventing and treating diabetes and its common comorbidities in older adults?
3.What issues need to be considered in individualizing treatment recommendations for older adults?
4.What current guidelines exist for treating diabetes in older adults?
5.What are consensus recommendations for treating older adults with or at risk for diabetes?
![Page 26: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/26.jpg)
![Page 27: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/27.jpg)
![Page 28: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/28.jpg)
![Page 29: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/29.jpg)
Polypharmacy
polypharmacy is defined as use of six or more prescription medicationsOlder adults with diabetes are at high risk of polypharmacy, increasing the risk of drug side effects and drug-to-drug interactions.
![Page 30: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/30.jpg)
![Page 31: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/31.jpg)
decreased socialization, sleep and appetite disturbances, higher health care costs and utilization
![Page 32: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/32.jpg)
![Page 33: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/33.jpg)
1.What is the epidemiology and pathogenesis of diabetes in older adults?
2.What is the evidence for preventing and treating diabetes and its common comorbidities in older adults?
3.What issues need to be considered in individualizing treatment recommendations for older adults?
4.What current guidelines exist for treating diabetes in older adults?
5.What are consensus recommendations for treating older adults with or at risk for diabetes?
![Page 34: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/34.jpg)
![Page 35: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/35.jpg)
![Page 36: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/36.jpg)
![Page 37: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/37.jpg)
![Page 38: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/38.jpg)
![Page 39: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/39.jpg)
1.What is the epidemiology and pathogenesis of diabetes in older adults?
2.What is the evidence for preventing and treating diabetes and its common comorbidities in older adults?
3.What issues need to be considered in individualizing treatment recommendations for older adults?
4.What current guidelines exist for treating diabetes in older adults?
5.What are consensus recommendations for treating older adults with or at risk for diabetes?
![Page 40: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/40.jpg)
![Page 41: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/41.jpg)
The prevalence and incidence rates of diabetes mellitus in elderly subjects (> 65 years) may be underestimated when using only fasting plasma glucose.The presence of isolated post-challenge hyperglycaemia (IPH) is common in older subjects and should alert the clinician to screen for cardiovascular disease and institute risk intervention strategies to minimise premature death.
![Page 42: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/42.jpg)
Lifestyle intervention is preferable to treatment with metformin in reducing the risks of type 2 diabetes in non-obese older adults with elevated fasting and postload plasma glucose levels.
Each functional assessment must include a measure of the three major domains of function: global/physical, cognitive and affective
![Page 43: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/43.jpg)
At initial assessment, all older patients aged less than 85 years with diabetes should have a cardiovascular risk assessment undertaken.
The ten-year risk of developing symptomatic cardiovascular disease should be calculated for all patients who have 2 or more risk factors to assess the need for primary prevention.
![Page 44: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/44.jpg)
For older patients with no comobidities a HBA1C of 7-7.5% should be targeted.
For frail patients where the hypoglycaemia risk is high the target HbA1c range should be 7.6-8.5%.
![Page 45: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/45.jpg)
Metformin should normally be first line therapy for overweight older adults with type 2 diabetes In non-obese older people with diabetes first line therapy with an insulin secretagogue (normally a sulphonylurea) or metformin should be offered.
![Page 46: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/46.jpg)
Glibenclamide should be avoided for newly diagnosed cases of type 2 diabetes in older adults (>70 years) because of the marked risk of hypoglycaemia. a DPP-4 inhibitor as an add-on to metformin when use of a sulphonylurea may pose an unacceptable hypoglycaemia risk can be considered in an older patient with diabetes
![Page 47: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/47.jpg)
When oral agents fail to lower glucose levels adequately, insulin may be given either as monotherapy or in combination with a sulphonylurea or metformin.
Use of a long-acting insulin analogue (e.g. glargine, determir) rather than NPH-insulin should be considered in older patients
![Page 48: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/48.jpg)
All physicians involved in the care of older patients with type 2 diabetes should assess the risk of hypoglycaemia and adjust therapy to minimise this risk.
Where the risk of hypoglycaemia is moderate (renal impairment, recent hospital admission) to high (previous history, frail patient with multiple comorbiditities, resident of a care home) use an agent with a lower hypoglycaemic potential, e.g. DPP4 inhibitor, lower risk sulphonylurea.
![Page 49: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/49.jpg)
In older patients with a sustained blood pressure (≥140/80 mmHg) – first line therapies can include: use of ACE inhibitors, angiotensin II receptor antagonists, long-acting calcium channel blockers, beta blockers or thiazide diuretics. Use of a perindopril-based regimen in older patients with type 2 diabetes (with or without hypertension) improves both microvascular and macrovascular outcomes.
![Page 50: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/50.jpg)
In subjects with no history of cardiovascular disease, a statin should be offered to patients with an abnormal lipid profile if their 10-year cardiovascular risk is high .
A statin should be offered to patients who have proven cardiovascular disease.
![Page 51: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/51.jpg)
Optimal glucose regulation may help to maintain cognitive function in older people with type diabetes.
To maintain vision in older patients with type 2 diabetes and established retinopathy, optimal blood pressure control (≤140/80 mmHg) and optimal glycaemia (HbA1c 7.0 – 7.5%) should be aimed for.
![Page 52: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/52.jpg)
For painful diabetic neuropathy gabapentin can be used in older patients and is superior to placebo in painful diabetic neuropathy and has fewer side-effects than tricyclic antidepressantsA multidisciplinary Falls Intervention programme should be offered to all patients with a history of a fall or who by virtue of other risk factors have a high risk of falling.
![Page 53: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/53.jpg)
1.What is the epidemiology and pathogenesis of diabetes in older adults?
2.What is the evidence for preventing and treating diabetes and its common comorbidities in older adults?
3.What issues need to be considered in individualizing treatment recommendations for older adults?
4.What current guidelines exist for treating diabetes in older adults?
5.What are consensus recommendations for treating older adults with or at risk for diabetes?
![Page 54: Diabetes and elderly](https://reader033.fdocuments.net/reader033/viewer/2022042716/55a667d71a28abdb668b45b4/html5/thumbnails/54.jpg)
54